Shattuck Labs, Inc.
STTK Healthcare Biotechnology
In the quarter to June 2026, revenue fell 10.3%, EPS grew 50.0% and free cash flow grew 1.01%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow STTK
Shattuck Labs, Inc. (STTK) EV/Sales
As of 16 October 2026, Shattuck Labs, Inc. (STTK) trades at a EV/Sales of 88.3×. Over the past ten years it has ranged from −66.2× (September 2023) to 501× (June 2021); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 31.4× | — |
| FY2024 | −2.0× | — |
| FY2023 | 116× | — |
| FY2022 | −1.8× | — |
| FY2021 | 3.0× | (93.84%) |
| FY2020 | 48.0× | 3,446.11% |
| FY2019 | 1.4× | 0.00% |
| FY2018 | 1.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 15.4× | — |
| Dec 2024 | −2.0× | — |
| Sep 2024 | 13.6× | (42.47%) |
| Jun 2024 | 23.6× | (80.87%) |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| VALN Valneva SE Sponsored ADR compare | 3.5× |
| STTK Shattuck Labs, Inc. | 88.3× |
| DBVT DBV Technologies S.A. compare | 124× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)